Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.74 |
| ▸ | NPC1 | O15118 | 7/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 5/20 | 0.74 |
| ▸ | PKM | P14618 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.56 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | ECE2 | P0DPD6 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899506 | 1.00 | RAB9A (0.74) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL9170780 | 0.91 | RAB9A (0.89) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL9170782 | 0.91 | RAB9A (0.89) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL659666 | 0.85 | RAB9A (1.00) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL659665 | 0.85 | RAB9A (1.00) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL30708719 | 0.85 | RAB9A (1.00) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL28443608 | 0.83 | RAB9A (0.80) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL8617773 | 0.83 | RAB9A (1.00) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL9594355 | 0.83 | RAB9A (1.00) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL9704021 | 0.83 | RAB9A (0.74) | RAB9ANPC1KDM4ELMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42376-E1 | Substituted 3-cyanoquinolines | WYETH HOLDINGS CORPORATION (US) | 2011-05-17 | — | — | US | claimed |
| EP-2253620-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2010-11-24 | — | — | EP | claimed |
| EP-1950201-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2008-07-30 | — | — | EP | claimed |
| US-6297258-B1 | USEFUL AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE. | AMERICAN CYANAMID COMPANY | 2001-10-02 | — | — | US | claimed |
| EP-1117649-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018740-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| US-9890187-B2 | Prototype systems of theranostic biomarkers for in vivo molecular management of cancer | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD. (CY) | 2018-02-13 | — | — | US | disclosed |
| US-20160376298-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD (CY) | 2016-12-29 | — | — | US | disclosed |
| EP-2896612-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2253620-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH HOLDINGS LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2253620-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009151910-A2 | COMBINATION PRODUCT OF RECEPTOR TYROSINE KINASE INHIBITOR AND FATTY ACID SYNTHASE INHIBITOR FOR TREATING CANCER | WYETH (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-1950201-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
| US-4962203-A | ANTIASTHMATIC, ANTIALLERGENIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS | MERCK FROST CANADA, INC. (CA) | 1990-10-09 | — | — | US | disclosed |
| EP-0206751-A2 | 2-Substituted quinolines, their preparation and use | MERCK FROSST CANADA INC. (CA) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | FASN, FRS2, FGFR1 | RAB9A 4363/4885NPC1 3495/4885KDM4E 2460/4885 |
| US-20160376298-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | TP53, MKI67, FLT3 | RAB9A 3409/4885NPC1 4408/4885KDM4E 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.